How personalization and psychedelics are revitalizing psychiatry
Nature October 28, 2026 DOI: 10.1038/d41586-026-03402-7 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Key points | States that over one billion people globally live with a mental-health condition and that these disorders are the world's leading cause of disability, with depression and anxiety costing an estimated US$1 trillion per year. Conventional pharmacological approaches are described as falling short, and two Nature News features are cited as indicating a shift toward personalized psychiatric care and psychedelic medicine. |
Abstract
Credit: Cole Burston/AFP/GettyMore than one billion people globally live with a mental-health condition. Collectively, these disorders are now the world’s leading cause of disability. Depression and anxiety alone cost the global economy an estimated US$1 trillion every year. The grand plan to transform psychiatry — by personalizing mental-health careConventional pharmacological approaches to improving mental health are falling short. However, two Nature News features this week report on innovations that indicate a shift is under way. One describes the personalization of psychiatric care; the other discusses developments in psychedelic medicine.